Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lumos Pharma, Inc. - Common Stock (NQ:LUMO)

4.340 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lumos Pharma, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Announces Participation in Investor Conferences in September
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Announces Departure of Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in World Orphan Drug Congress USA
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency
From Lumos Pharma, Inc.
Via GlobeNewswire
News headline image
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022
From Lumos Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.